[1] 中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.冠心病双联抗血小板治疗中国专家共识[J].中华心血管病杂志,2021,49(5):432-454.
[2] Valgimigli M,Bueno H,Byrne RA,et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).Eur Heart J,2018,39:213-260.
[3] 王云云,乌云其达木改,周强.PCI术后标准双联抗血小板治疗不耐受的处理策略[J].临床心血管病杂志,2021,37(5):406-410.
[4] Lee JY,Sung KC,Choi HI.Comparison of aspirin and indobufen in healthy volunteers[J].Platelets,2016,27(2):105-109.
[5] De Caterina R,Giannessi D,Bernini W,et al.A prostacyclin-sparing effect of indobufen vs.aspirin[J].Thromb Haemost,1996 Mar,75(3):510-4.
[6] 张婉秋,严光.老年慢性心衰患者生存质量影响因素及健康需求分析[J].系统医学,2020,5(7):55-58.
[7] 陈玲,陈彬.合理用药自我效能对冠心病患者服药依从性行为阶段的影响[J].中华现代护理杂志,2016,22(31):4508-4511.
[8] Sherbourne CD,Hays RD,Ordway L,et al.Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study[J].J Behav Med,1992 Oct,15(5):447-468.
[9] Fosburgh D.Aspirin and clopidogrel resistance[J].Mayo Clinic proceedings,2006,81(7):989.
[10] Bhatt DL,Grosser T,Dong JF,et al.Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus[J].J Am Coll Cardiol,2017 Feb 14,69(6):603-612.
[11] 霍勇,王拥军,谷涌泉等.常用口服抗血小板药物不耐受及低反应性人群诊疗专家共识[J].中华心血管病杂志,2021,04(1):1-13.
[12] 敖俪元. 肠溶阿司匹林治疗冠心病的临床疗效及其诱发上消化道出血的相关因素分析[J].心血管病防治知识(学术版),2020,10(4):26-28.
[13] 李阳,于海初.急性心肌梗死经皮冠状动脉介入治疗术后应用替格瑞洛联合阿司匹林治疗发生脑出血一例[J].中国循环杂志,2016,31(12):1164.
[14] 林丽容,吴志勇,黄鼎三,等.急性冠脉综合征PCI术后痛风急性发作的相关因素分析[J].医学理论与实践,2020,33(20):3364-3365.
[15] 程希,蒋学华,龙恩武,等.阿司匹林联合呋塞米引起糖尿病肾病患者痛风急性发作1例的药物治疗评价[J].中国医药导报,2018,15(2):164-167,171.
[16] Marzo A,Crestani S,Fumagalli I,et al.Endoscopic evaluation of the effects of indobufen and aspirin in healthy volunteers[J].American journal of therapeutics,2004,11(2):98-102.
[17] Latib A,Ielasi A,Ferri L,et al.Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen[J].Int J Cardiol,2013,165(3):444-447.
[18] 刘芳,王建文.吲哚布芬作用机制及临床应用的研究现状[J].中国临床药理学杂志,2021,37(13):1724-1727.
[19] 白辰,李京倖,于洋,等.吲哚布芬与阿司匹林预防冠状动脉旁路移植术后桥血管再狭窄的随机对照试验[J].中华心血管病杂志,2022,50(5):466-470.
[20] Lu H,Xu L,Zhao X,et al.Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label,Endpoint-blinded,Non-inferiority Trial. Circulation,2022, Nov 6.
[21] De Caterina R,Giannessi D,Bernini W,et al.A prostacyclin-sparing effect of indobufen vs.aspirin[J].Thrombosis and haemostasis, 1996, 75(3):510-514.
[22] 谢娟,李正胜,卢晶晶,等.吲哚布芬预防血液透析患者动静脉内瘘血栓形成[J].贵州医科大学学报,2017,42(5):607-610.
[23] Shi QP,Luo XY,Zhang B,et al.Effect of indobufen vs.aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: An open-label crossover study[J].Front Pharmacol,2022,13:950719. |
